Search clinical trials for: Technosphere Insulin

Total 2806 results

Novo Nordisk A/S

Completed

Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting or Switching to Biphasic Insulin Aspart 30 Treatment

Diabetes Mellitus, Type 2 | Diabetes

Denmark
Novo Nordisk A/S

Completed

Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin (COMMIT)

Diabetes Mellitus, Type 2 | Diabetes

Slovakia
Novo Nordisk A/S

Completed

Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin

Diabetes Mellitus, Type 2 | Diabetes

Czech Republic
Novo Nordisk A/S

Completed

Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Effect of Biphasic Insulin Aspart 30 on Blood Glucose Control in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Russian Federation
Novo Nordisk A/S

Completed

Safety of NovoMix® 30 or Levemir® for Treatment of Type 2 Diabetics in Macedonia

Diabetes Mellitus, Type 2 | Diabetes

Macedonia, The Former Yugoslav Republic of
Novo Nordisk A/S

Completed

Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 in Healthy Volunteers

Healthy | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

China
Geropharm

Completed

A Study to Compare Pharmacokinetics and Pharmacodynamics of GP-40081 to NovoMix® 30 Penfill® in Healthy Subjects

Clamp Study

Russian Federation
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Macedonia, The Former Yugoslav Republic of
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart (30, 50 and 70) and Insulin Aspart in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

An Observational Study of Efficacy and Safety of Modern Insulin in Diabetes Patients Switched From Anti-diabetic Treatment

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Saudi Arabia
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes (SimpleMix™)

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom, Poland, Spain, India, Argentina, China
Novo Nordisk A/S

Completed

Observational Study of Safety of NovoMix® 30 Treatment for Type 2 Diabetes (Start)

Diabetes Mellitus, Type 2 | Diabetes

Sweden
Novo Nordisk A/S

Completed

Safety of Treatment Initiation With Biphasic Insulin Aspart 30 in Hospitalised Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland
Novo Nordisk A/S

Completed

Prandial Orientated Biphasic Insulin Aspart 30 Therapy - the Physiological Premix Insulin Therapy for Type 2 Diabetes (ProMix)

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Post Marketing Surveillance Study of Biphasic Insulin Aspart 30

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Korea, Republic of
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Norway, United Kingdom, Sweden, Finland
Novo Nordisk A/S

Completed

Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin (Mix2Mix)

Diabetes Mellitus, Type 2 | Diabetes

Belgium, Luxembourg
Julphar Gulf Pharmaceutical Industries
Profil Institut für Stoffwechselforschung GmbH

Completed

Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin 30/70 and Huminsulin® Profil III

Diabetes Mellitus

Germany
Novo Nordisk A/S

Completed

Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Bosnia and Herzegovina
Novo Nordisk A/S

Completed

Comparing the Efficacy and Safety of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 on Blood Sugar Control in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 50 to Biphasic Insulin Aspart 70 in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark
Novo Nordisk A/S

Completed

Comparison of Two Biphasic Insulin Aspart 30 Formulations (Current and New Formulation) in Healthy Volunteers

Healthy | Diabetes

United States
Geropharm

Completed

Comparative Study of Rinsulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (GEROPHARM LLC, Russia) and Humulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (Lilly France, France) Using the Euglycemic Hyperinsulinemic Clamp Method

Pharmacokinetics | Bioequivalence

Russian Federation
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Japanese Subjects

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Malaysia, Australia, Taiwan, Thailand, Hong Kong, Singapore, Philippines
Novo Nordisk A/S

Completed

Investigation of the Pharmacokinetic Properties of Biphasic Insulin Aspart 50 in Healthy Chinese Subjects

Healthy | Diabetes

China
Novo Nordisk A/S

Completed

Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 Diabetes (PRESENT)

Diabetes Mellitus, Type 2 | Diabetes

Korea, Republic of
Novo Nordisk A/S

Completed

Observational Study on Safety and Efficacy of Biphasic Insulin Aspart in Type 2 Diabetes Patients

Diabetes Mellitus, Type 2 | Diabetes

Israel
Mannkind Corporation

Completed

Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function

Diabetes Mellitus | Mild Nephropathy | Moderate Nephropathy

United States
Novo Nordisk A/S

Completed

Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs

Diabetes Mellitus, Type 2 | Diabetes

Mexico
Novo Nordisk A/S

Completed

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

Diabetes | Type 2 Diabetes Mellitus

Taiwan, Turkey, India, Algeria, Hong Kong, China, Ukraine
Novo Nordisk A/S

Completed

Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Slovakia
Novo Nordisk A/S

Completed

Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Norway, Sweden
Novo Nordisk A/S

Completed

Observational Study to Evaluate the Safety of NovoMix® 30 FlexPen®

Diabetes Mellitus, Type 2 | Diabetes

Tunisia
Novo Nordisk A/S

Completed

Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands (SWITCH)

Diabetes Mellitus, Type 2 | Diabetes

Netherlands
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

Jordan
Novo Nordisk A/S

Completed

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Male Subjects

Healthy | Diabetes

South Africa
Novo Nordisk A/S

Completed

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Japanese Subjects

Healthy | Diabetes

Japan
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 With Metformin in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

South Africa
Sanofi

Terminated

Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction (INTENSIVE)

AMI

Canada, Brazil, United States, Argentina, Mexico
Novo Nordisk A/S

Completed

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Male Subjects

Healthy | Diabetes

South Africa
Sanofi

Completed

Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy (Insuman-C25-CN)

Type 2 Diabetes Mellitus

China
University of Aarhus

Completed

Intracellular Counter-regulatory Mechanisms Following Low Blood Glucose

Hypoglycemia | Diabetes Mellitus Type I

Denmark

3

Subscribe